• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
opioid epidemic

Johnson & Johnson Accused of Dodging Liability for Its Alleged Role in Opioid Epidemic

By
Jef Feeley
Jef Feeley
and
Bloomberg
Bloomberg
Down Arrow Button Icon
By
Jef Feeley
Jef Feeley
and
Bloomberg
Bloomberg
Down Arrow Button Icon
July 15, 2019, 3:40 PM ET
A used syringe in the dirt.
NEW YORK, NEW YORK - MARCH 13: Hypodermic needles litter the ground in the South Bronx on March 13, 2019 in New York City. America's drug makers are finding themselves under increased legal scrutiny by states and attorney generals as hundreds of lawsuits tied to the deadly opioid epidemic have been filed against them. Pharmacy chains and drug makers such as Purdue Pharma, Johnson & Johnson and CVS are finding their internal documents and research with opioids being used in court against them in lawsuits claiming that they helped to fuel the nationwide epidemic which has killed tens of thousands of Americans. (Photo by Spencer Platt/Getty Images)Spencer Platt–Getty Images

Even after illegally promoting opioid painkillers to reap billions of dollars in profit over the past two decades, Johnson & Johnson has accepted “zero responsibility’’ for its central role in fueling a public-health crisis, Oklahoma’s top law-enforcement official told a trial judge.

J&J engaged in a “cunning” scheme to dupe doctors into over-prescribing addictive medications that “wrecked thousands” of families in the state, Oklahoma Attorney General Mike Hunter said during closing arguments Monday. The trial in Oklahoma City is the first of more than 1,900 local U.S. government lawsuits against drug makers and distributors over the fallout from opioid abuse.

“They blame everyone else,” Hunter told Judge Thad Balkman, who is hearing the case without a jury. “The only question is whether the Oklahoma taxpayer or the kingpin” should pick up the tab for the costs of addressing the state’s epidemic, the attorney general said.

J&J disputes the state’s allegations and refuses to settle the dispute like their rivals. Larry Ottaway, a J&J lawyer, told Balkman the drugmaker is being used as a scapegoat for other companies’ missteps.

“There are no easy answers” to the state’s opioid-addiction problems, and accusing J&J of being “the head of some opioid cartel” isn’t productive, Ottaway said in his closing argument.

At the end of presentations by both sides, Balkman said he will review the evidence and announce his opinion in about a month.

Hunter claims more than 4,000 Oklahomans died over the past two decades from opioid abuse and thousands were left hooked on pills. Similar allegations against market leader Purdue Pharma LP led to a $270 million settlement before the trial began more than a month ago, while Teva Pharmaceutical Industries Ltd. agreed to pay $85 million.

Government officials across the U.S. are seeking to collect billions of dollars as compensation for their costs in dealing with opioid addiction. The outcome in Oklahoma — where J&J is facing allegations under the state’s public-nuisance law — could impact claims and settlement talks involving other states, cities and counties, who are using the same legal theory to hold the drugmaker liable.

Unfair Blame

J&J argues it’s being blamed for the bad acts of others, including Purdue and Teva. New Brunswick, New Jersey-based J&J has also fought the state’s request for as much as $17.5 billion over 30 years in reimbursement for current and future outlays to cope with the epidemic’s costs.

Hunter claims J&J is a “kingpin’’ of the opioid crisis because some of its former overseas units once produced and processed opium poppies used as the active-pharmaceutical ingredient in opioids. J&J officials vigorously rejected such characterizations. The company said it sold those units and that it was hardly the only one growing poppies for medical uses.

“J&J paid ’em to push pills,” Brad Beckworth, a lawyer representing the state, said of the company’s opioid-promotion strategy with doctors. “That’s what drug dealers do.”

Beckworth, the state’s lead lawyer on the case, also described J&J as “a corrupt company” that only cared about making money when it came to promoting and supplying opioids.

Oklahoma’s lawyers presented evidence showing Australian poppy cultivator Tasmanian Alkaloids sold the key ingredient for opioid medications to other manufacturers, including Purdue and Teva.

During the trial, J&J and its Janssen unit provided testimony from an expert on world-wide drug smuggling who rejected the state’s claim that the opioid promotions by the company were similar to those of illegal traffickers.

J&J’s attorney also dismissed the state’s claims the company’s sales reps were tasked with duping Oklahoma doctors into ramping up opioid prescriptions regardless of the risks and lavishly awarded for doing so.

“The state would have you believe we marshaled an army to come here to mislead doctors about risk and benefits of opioids,” Ottaway said. “Not true.”

He also asked Balkman to remember the state didn’t provide evidence from any Oklahoma doctors who could support claims that J&J or Janssen officials misled them about the addiction and overdose risks of opioids.

The case is State of Oklahoma v. Purdue Pharma LP, CJ-2017-816, Cleveland County, Oklahoma, District Court (Norman).

More must-read stories from Fortune:

—Change Healthcare CEO: IPO marks time to change healthcare

—Facebook cracks down on miracle cures and scammy diet pills

—Commentary: Why Alexa gaining medical skills could be bad for health care

—CVS wants to make your drugstore your doctor

—Listen to our new audio briefing, Fortune 500 Daily

Follow Fortune on Flipboard to stay up-to-date on the latest news and analysis.

About the Authors
By Jef Feeley
See full bioRight Arrow Button Icon
By Bloomberg
See full bioRight Arrow Button Icon

Latest in

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
Fortune Secondary Logo
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in

AIAnthropic
Anthropic CEO Dario Amodei says ‘we are patriotic Americans’ committed to defending the U.S. but won’t budge on ‘red lines’
By Jason MaFebruary 28, 2026
47 minutes ago
Middle EastIran
Iran is now on ‘death ground’ amid existential threat from U.S. attacks and could ‘go big’ in retaliation, former NATO commander warns
By Jason MaFebruary 28, 2026
3 hours ago
trump
LawTariffs
‘Why shouldn’t we get our money back too?’ Normal people are starting to demand Trump tariff refunds
By Mae Anderson and The Associated PressFebruary 28, 2026
3 hours ago
david ellison
Arts & EntertainmentHollywood
20 years ago, David Ellison’s flop as an actor stressed him out so much he went to the hospital. Now he’s set to own Paramount and Warner
By Matt Sedensky and The Associated PressFebruary 28, 2026
4 hours ago
warren
InvestingBerkshire Hathaway
Berkshire Hathaway shareholders just woke up to a letter by someone other than Warren Buffett
By Josh Funk and The Associated PressFebruary 28, 2026
4 hours ago
trump
PoliticsWhite House
Trump says Cuba has ‘no money’ and ‘maybe we’ll have a friendly takeover’
By Will Weissert and The Associated PressFebruary 28, 2026
4 hours ago

Most Popular

placeholder alt text
Success
Japanese companies are paying older workers to sit by a window and do nothing—while Western CEOs demand super-AI productivity just to keep your job
By Orianna Rosa RoyleFebruary 27, 2026
1 day ago
placeholder alt text
Success
Walmart exec says U.S. workforces needs to take inspiration from China where ‘5 year-olds are learning DeepSeek’
By Preston ForeFebruary 27, 2026
1 day ago
placeholder alt text
Personal Finance
Current price of gold as of February 27, 2026
By Danny BakstFebruary 27, 2026
1 day ago
placeholder alt text
Law
China's government intervenes to show Michigan scientists were carrying worms, not biological materials
By Ed White and The Associated PressFebruary 26, 2026
2 days ago
placeholder alt text
Commentary
'The Pitt': a masterclass display of DEI in action 
By Robert RabenFebruary 26, 2026
2 days ago
placeholder alt text
Economy
Come 2030, the U.S. deficit will be worth 5.9% of GDP—more than spending on Social Security, and equal to major health programs
By Eleanor PringleFebruary 26, 2026
2 days ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.